Home/Filings/4/0001439222-25-000017
4//SEC Filing

Milanova Tsveta 4

Accession 0001439222-25-000017

CIK 0001439222other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 4:12 PM ET

Size

13.4 KB

Accession

0001439222-25-000017

Insider Transaction Report

Form 4
Period: 2025-03-01
Milanova Tsveta
Chief Commercial Officer
Transactions
  • Award

    Restricted stock units

    2025-03-01+12,00012,000 total
    Common stock (12,000 underlying)
  • Sale

    Common stock

    2025-03-03$35.54/sh1,681$59,74322,892 total
  • Exercise/Conversion

    Restricted stock units

    2025-03-015,66711,333 total
    Common stock (5,667 underlying)
  • Award

    Stock options (right to buy)

    2025-03-01+43,50043,500 total
    Exercise: $35.54Exp: 2035-03-01Common stock (43,500 underlying)
  • Exercise/Conversion

    Common stock

    2025-03-01+5,66724,573 total
Footnotes (5)
  • [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F3]The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F4]This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.
  • [F5]The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001957180

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:12 PM ET
Size
13.4 KB